Brief: Inmagene Successfully Doses First Patient In Adaptive Trial Of IMG-007
01/07/2025 22:37
July 1 (Reuters) - Ikena Oncology Inc IKNA.O: IKENA ONCOLOGY INC - INMAGENE SUCCESSFULLY DOSES FIRST PATIENT IN ADAPTIVE TRIAL OF IMG-007 - SEC FILING IKENA ONCOLOGY INC: INMAGENE EXPECTS TOPLINE DATA IN Q4 2026 Further company coverage: IKNA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ImageneBio
See all newsImageneBio Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: ImageneBio - Appoints Yanina Grant-Huerta As Chief Financial Officer Effective July 20, 2026 - SEC Filing
ImageneBio Inc expected to post a loss of 89 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune
U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma